Home › NDC Lookup › RxCUI directory › RxCUI 352307

Aripiprazole 10 MG Oral Tablet [Abilify] — RxCUI 352307

RxNorm drug concept · Semantic branded drug
RxCUI 352307 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 15 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI352307
Official nameAripiprazole 10 MG Oral Tablet [Abilify]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAbilify 10 MG Oral Tablet
FDA products mapped6
Package NDCs mapped15
Reported Medicaid activity (SDUD)2,817 prescriptions · 13 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Aripiprazole: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Not at all — aripiprazole actually has several approved uses. It's prescribed for schizophrenia, manic or mixed episodes of Bipolar I Disorder, and as an add-on to antidepressants...
  • What exactly is aripiprazole used for — is it just for schizophrenia?
  • It typically takes up to two weeks for aripiprazole to build up to stable levels in your body, so don't be discouraged if you don't feel a difference right away. For some condition...
  • How long does it take before I notice it working?
📖 Read our full Aripiprazole guide →

🕸️ Concept Web — How Aripiprazole 10 MG Oral Tablet [Abilify] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Aripiprazole 10 MG Oral Tablet [Abilify] RxCUI 352307

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Aripiprazole 89013
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Abilify 352393
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Aripiprazole Oral Tablet 378301
    • Aripiprazole Oral Product 1158261
    • Aripiprazole Pill 1158262
    • Aripiprazole Oral Tablet [Abilify] 368563
    • Abilify Oral Product 1165949
    • Abilify Pill 1165950
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Aripiprazole 10 MG Oral Tablet SCD · 349545
  • Aripiprazole 10 MG SCDC · 350663
  • Aripiprazole Oral Tablet SCDF · 378301
  • Aripiprazole Oral Product SCDG · 1158261
  • Aripiprazole Pill SCDG · 1158262

Brand-Name Concepts

  • Aripiprazole 10 MG [Abilify] SBDC · 576003
  • Aripiprazole Oral Tablet [Abilify] SBDF · 368563
  • Abilify Oral Product SBDG · 1165949
  • Abilify Pill SBDG · 1165950
  • Abilify BN · 352393

📦 FDA Products & Package NDCs

6 products · 15 package NDCs
15 package NDCs map to RxCUI 352307 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59148-0006-13 30 TABLET in 1 BOTTLE, PLASTIC (59148-006-13) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0006-92 7 TABLET in 1 BLISTER PACK (59148-006-92) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0007-13 30 TABLET in 1 BOTTLE, PLASTIC (59148-007-13) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0007-35 100 TABLET in 1 BLISTER PACK (59148-007-35) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0007-94 7 TABLET in 1 BLISTER PACK (59148-007-94) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0008-13 30 TABLET in 1 BOTTLE, PLASTIC (59148-008-13) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0008-35 100 TABLET in 1 BLISTER PACK (59148-008-35) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0008-95 7 TABLET in 1 BLISTER PACK (59148-008-95) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0009-13 30 TABLET in 1 BOTTLE, PLASTIC (59148-009-13) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0009-35 100 TABLET in 1 BLISTER PACK (59148-009-35) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0009-95 7 TABLET in 1 BLISTER PACK (59148-009-95) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0010-13 30 TABLET in 1 BOTTLE, PLASTIC (59148-010-13) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0010-35 100 TABLET in 1 BLISTER PACK (59148-010-35) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0011-13 30 TABLET in 1 BOTTLE, PLASTIC (59148-011-13) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
59148-0011-35 100 TABLET in 1 BLISTER PACK (59148-011-35) ABILIFY Otsuka America Pharmaceutical, Inc. 2002-11-15
Observed labelers: Otsuka America Pharmaceutical, Inc. (15) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.